We were delighted to talk with Dr Brian Van Tine (Washington University School of Medicine, Saint Louis, MO, US) around the APROMISS study, investigating the efficacy and safety of AL3818 hydrochloride monotherapy in patients with metastatic or advanced synovial sarcoma.
The abstract ‘A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma (NCT03016819)‘ (abstract number 11505) was presented at the 2021 ASCO Annual Meeting.
Questions
- Could you tell us a little about catequentinib, its mechanism of action and applications in oncology? (0:13)
- What were the aims, design and inclusion criteria of the APROMISS study? (0:34)
- What were the efficacy findings, and how clinically meaningful are these? (1:15)
- What was the impact of prior pazopanib use on the efficacy of catequentinib and dacarbazine? (1:47)
- What were the safety and tolerability findings of the study? (2:30)
Disclosures: Brian Van Tine discloses research grants from: Pfizer, Mereck, Tacon Pharm and GSK; Consultant for: ADRx, Ayala Pharm, Cytokinetics, Bayer, Adaptimmune, Bionest Partners, GSK, Intellisphere LLC.; Advisory Board for: Adaptimmune, Apexigen Inc., Daiichi Sankyo, Deciphera Pharm, Epizyme, GSK, Lilly and Novartis. Board Member at Polaris.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 ASCO Annual Meeting.
